CCDC 1052960: Experimental Crystal Structure Determination
Michael A. Brodney(Vertex Pharmaceuticals (United States)), Brian T. O’Neill(Pfizer (United States)), Cathleen Gonzales, Aijia Yu(WuXi AppTec (China)), David Riddell(Eli Lilly (United States)), Kevin Parris, Erik LaChapelle(Pfizer (United States)), Luis Martinez-Alsina(Pfizer (United States)), Jayvardhan Pandit(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Loren Price(Pfizer (United States)), Xinjun Hou(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Kevin E. Henegar(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Murray(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), Peter Mikochik(Pfizer (United States)), Mark W. Bundesmann(Pfizer (United States)), Subas M. Sakya(Pfizer (United States)), Eric F. Johnson(Pfizer (United States)), Christopher R. Butler(Pfizer (United States)), Yong Zhang(China Institute of Atomic Energy), Ricardo Lira(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Bruce N. Rogers(Pfizer (United States)), Jason K. Dutra(Pfizer (United States)), Ying Fan, Gabriela Barreiro(Pfizer (United States))
Cited by 0
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460